Careers  |  Sign In  |  Register  |   Twitter

Agenus Shows Effectiveness of Herpes Vaccine

Reuters reports that Agenus Inc. has released data on its experimental genital herpes vaccine, HerpV. The mid-stage trial recruited 80 patients with a history of 1-9 reoccurences of genital herpes in the past 12 months and examined virus release before and after three infections of HerpV. The vaccine is thought to work by injection of QS-21 Stimulon, an “immune booster.” According to Agenus, the vaccine “reduced the rate at which patients released the virus” by 15%, reducing the likelihood of infecting others.” The vaccine also reduced the severity of the virus by 34%.

Read the article published by Reuters.